Kuros Biosciences
- Company typePublic
- Founded2000
- HeadquartersSchlieren, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Kuros Biosciences firmographics
Firmographics- Name
- Kuros Biosciences
- Legal name
- Kuros Biosciences AG
- Website
- https://kurosbio.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Kuros Biosciences industry classification
Industry- Product category
- Orthobiologic Bone Grafts
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Kuros Biosciences is headquartered
LocationHeadquarters
- HQ city
- Schlieren
- HQ country
- Switzerland
- HQ region
- Europe
Offices5 records
Markets served
Kuros Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- MagnetOs Bone Graft Product Sales: Medical device company generating revenue from sale of MagnetOs bone graft products across spine, extremities, and trauma applications. Revenue grew 72% YoY to $146.1M in 2025. Achieved first group-level profitability with net income of $2.6M in 2025 vs net loss of $4.8M in 2024. Gross profit margin of 87%.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels6 records
Kuros Biosciences product offering
Product offeringCore offering
Kuros Biosciences develops, manufactures and commercializes the MagnetOs family of synthetic bone graft substitutes powered by proprietary NeedleGrip submicron surface technology. The portfolio comprises Granules, Putty, Easypack Putty, Flex Matrix and the MIS Delivery System, used by spine, extremities and trauma surgeons to fill bone voids and promote fusion in spinal fusion, foot/ankle, and orthopedic trauma procedures. Products are sold through direct sales, strategic distribution agreements (including Medtronic) and regional distributors across more than 20 markets.
Product overview
Kuros Biosciences develops and commercializes the MagnetOs family of bone graft products powered by NeedleGrip submicron surface technology. The portfolio consists of five main formulations: MagnetOs Granules (the foundational granular form), MagnetOs Putty (moldable formulation), MagnetOs Easypack Putty (syringe-dispensed formulation), MagnetOs Flex Matrix (matrix form for interbody fusion), and MagnetOs MIS Delivery System (minimally invasive delivery instrument). All products are based on biphasic calcium phosphate with the proprietary NeedleGrip surface technology that stimulates bone growth by polarizing macrophages to the M2 pro-healing phenotype. The products serve spine, extremities (foot and ankle), and trauma markets with various formulations optimized for different surgical approaches and anatomical regions.
Differentiator
Problem solved
Functional benefit
Brands
- MagnetOs: Product brand for bone graft technologies including Granules, Putty, Easypack Putty, Flex Matrix, and MIS Delivery System
- NeedleGrip
- Project Fusion
Products and services
- MagnetOs Granules Foundational granular bone graft based on biphasic calcium phosphate with NeedleGrip submicron surface technology, used to fill amorphous and contained or semi-contained voids in spine and extremities procedures. 510(k)-cleared since 2017 and sold to spine and orthopedic surgeons.
- MagnetOs Putty Moldable bone graft with NeedleGrip surface technology that can be warmed in hands and molded for filling voids in joint fusion or traumatic indications of the foot, ankle and upper extremity. Stores at ambient temperature and requires no preparation time. Sold to orthopedic extremities and trauma surgeons.
- MagnetOs Easypack Putty Syringe-dispensed, ready-to-use putty formulation for rapid application in joint fusion or void filling in extremities. Dispensed directly into the palm, maintains presence during compression and resists irrigation. Sold to extremities, spine and trauma surgeons.
- MagnetOs Flex Matrix Matrix-formulated bone graft with NeedleGrip surface technology designed for spinal fusion procedures, FDA-cleared for interbody use in posterolateral lumbar fusion. Sold to spine surgeons.
- MagnetOs MIS Delivery System FDA-cleared minimally invasive surgery delivery system that enables delivery of MagnetOs bone graft through smaller incisions in spine procedures. Sold to spine surgeons performing minimally invasive fusion.
Quantifiable outcome
- 79% fusion rate with MagnetOs vs 47% autograft in Level I clinical trial
- +4 more outcomes
Companies that use Kuros Biosciences
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Kuros Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Kuros Biosciences partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, regional and major.
- Medtronic Spinal DivisioncoreExclusive strategic agreement with Medtronic spinal division announced January 2025. Kuros Biosciences USA, Inc. entered into this partnership to expand distribution and market access for MagnetOs bone graft products.
- Middle East DistributorsregionalLaunch of MagnetOs in Middle East countries including regulatory approvals in Saudi Arabia in October 2024.
- Top 3 Spine CompanymajorSales distribution agreement with a top 3 spine company announced August 2023. This partnership provides broader market reach through the partner's established distribution network.
- APAC DistributorsregionalFirst APAC distributor agreement signed July 2019 for distribution of MagnetOs products in Asia-Pacific markets.
Scale indicators12 records
Recent moves9 records
Expansion highlights6 records
Kuros Biosciences competitors and assessment
Company assessmentBroad incumbents
- Medtronic (Spinal & Biologics division): The global spine market leader with a broad spinal hardware and biologics portfolio (including Infuse BMP). Comparable to Kuros as both a direct competitor in orthobiologics and the strategic partner distributing MagnetOs in the US since January 2025.
- DePuy Synthes (Johnson & Johnson): Major spine, trauma, and extremities franchise with a broad bone graft and biologics offering. Comparable to Kuros because it competes across the same spine, extremities, and trauma markets and employs several Kuros senior leaders (e.g., incoming COO I.V. Hall, CBO John Griffin, SVP Todd Stohler).
- Stryker (Spine & Orthopaedics): Diversified medtech with spine, orthopaedics, and biologics offerings (including the legacy Wright Medical extremities portfolio). Directly comparable to Kuros in spine hardware adjacencies and extremities bone graft markets, and a known employer of several Kuros senior commercial leaders.
Direct peers
- Orthofix Medical (SeaSpine): Spine and extremities-focused medtech with bone graft and biologic substitutes (including the Trinity ELITE allograft line). Highly comparable to Kuros as a US-listed pure-play in spine/extremities orthobiologics, and recent employer of SVP Joe Ross.
- NuVasive / Globus Medical: Pure-play spine companies with overlapping hardware, MIS delivery, and biologics offerings (Globus acquired NuVasive in 2023). Comparable to Kuros as direct competitors in spine fusion procedures and in MIS delivery technology where Kuros's new MagnetOs MIS Delivery System is positioned.
- Integra LifeSciences: Spine, orthobiologics, and extremity-focused medtech with bone graft substitutes (e.g., Accell Evo3, Integra OS). Comparable to Kuros as a competitor across spine and extremities bone graft indications, and a previous employer of SVP HR Laura Rosa.
- Alphatec Holdings: US-listed pure-play spine company focused on MIS and lateral fusion approaches. Comparable to Kuros as a spine-focused competitor with overlapping surgeon call points and a similar growth-stage profile in the US spine market.
- Bioventus: Orthobiologics company with bone graft substitutes (e.g., Signafuse, BioMatrix), pain therapies, and restorative treatments. Directly comparable to Kuros as an orthobiologics competitor addressing spine fusion and extremities bone healing indications.
- Xtant Medical: Pure-play orthobiologics company offering allograft and synthetic bone graft products (e.g., OsteoVive, 3Demin) for spine and trauma. Comparable to Kuros as a direct competitor in synthetic and traditional bone graft substitutes targeting spine and extremities surgeons.
Emerging players
- SI-BONE: Specialized spine device company with proprietary triangular implants for sacropelvic conditions. Comparable to Kuros as a small-cap, evidence-driven spine medtech addressing niche but adjacent indications and competing for surgeon mindshare in academic spine centers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Kuros Biosciences social profiles
Digital presenceKuros Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kuros Biosciences leadership team
Management profileNumber of profiles
Profiles17 records
Kuros Biosciences subsidiaries and ownership
Company hierarchySubsidiaries2 records
Kuros Biosciences funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kuros Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kuros Biosciences
What does Kuros Biosciences do?
Kuros Biosciences develops, manufactures and commercializes the MagnetOs family of synthetic bone graft substitutes powered by proprietary NeedleGrip submicron surface technology. The portfolio comprises Granules, Putty, Easypack Putty, Flex Matrix and the MIS Delivery System, used by spine, extremities and trauma surgeons to fill bone voids and promote fusion in spinal fusion, foot/ankle, and orthopedic trauma procedures. Products are sold through direct sales, strategic distribution agreements (including Medtronic) and regional distributors across more than 20 markets.
Is Kuros Biosciences a public or private company?
Kuros Biosciences is a public company. It is classified as public and is currently operating.
When was Kuros Biosciences founded?
Kuros Biosciences was founded in 2000. It employs 51 to 100 people.
Where is Kuros Biosciences based?
Kuros Biosciences is headquartered in Schlieren, Switzerland, in the Europe region.
How does Kuros Biosciences make money?
One revenue line is on record: magnetOs Bone Graft Product Sales.
Who are Kuros Biosciences's main competitors?
Broad incumbents on record are Medtronic (Spinal & Biologics division), DePuy Synthes (Johnson & Johnson) and Stryker (Spine & Orthopaedics). Direct peers are Orthofix Medical (SeaSpine), NuVasive / Globus Medical, Integra LifeSciences, Alphatec Holdings, Bioventus and Xtant Medical. SI-BONE is listed as an emerging player.
Does Kuros Biosciences have an API?
No public API is recorded for Kuros Biosciences.
What industry is Kuros Biosciences in?
Kuros Biosciences's product category is Orthobiologic Bone Grafts. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHAEAC, Spine Implants & Motion Preservation (Fusion/Disc/Interspinous). Its NAICS code is 339113 and its SIC code is 3842.